APYX MEDICAL CORPORATION ANNOUNCES TWO PEER-REVIEWED CLINICAL PUBLICATIONS EVALUATING RENUVION’S HELIUM PLASMA TECHNOLOGY
CLEARWATER, FL — OCTOBER 20, 2020 – Apyx® Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today announced the publication of two separate peer-reviewed articles published in the journal, Dermatological Reviews.
“We are very pleased to announce these two peer-reviewed clinical publications, which represent important additions to the portfolio of clinical evidence supporting the use of Renuvion,” said Charlie Goodwin, President and Chief Executive Officer. “Specifically, these publications looked retrospectively at the use of Renuvion when used independently of liposuction for subdermal coagulation in the neck and when used in combination with liposuction for subdermal coagulation in various treatment areas of the body. The data from the retrospective studies in these publications serves to strengthen the risk/benefit profile of Renuvion’s Helium Plasma Technology. Building on the results of these studies, we look forward to the continued expansion of our portfolio of clinical evidence to demonstrate the clinical utility of our Renuvion technology and facilitate broad-based adoption in the market.”
The peer-reviewed clinical publications are:
“A Retrospective Chart Review of Subdermal Neck Coagulation Using Helium Plasma Technology”:
This journal article consisted of two separate retrospective chart review studies (Study 1, n=15 and Study 2, n= 13) performed using data from subjects who had undergone helium plasma treatment with Renuvion for subdermal coagulation to achieve tissue contraction in the neck.
Article citation: Doolabh V, Ruff P. A Retrospective Chart Review of Subdermal Neck Coagulation Using Helium Plasma Technology. Dermatological Reviews. 2020;1–8. https://doi.org/10.1002/der2.32
“Safety and Efficacy of Helium Plasma for Subdermal Coagulation”:
This journal article consisted of two separate retrospective chart review studies (Study 1, n= 37 and Study 2, n= 148) performed using data from subjects who had undergone liposuction followed by subdermal coagulation using Renuvion. Subjects were treated in a variety of anatomical areas, such as the abdomen, arms, and neck.
Article citation: Ruff PG, Doolabh V, Zimmerman EM, Gentile RA. Safety and efficacy of helium plasma for subdermal coagulation. Dermatological Reviews. 2020;1–7. https://doi.org/10.1002/der2.34
About Apyx Medical Corporation
Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people’s lives through innovative products in the cosmetic and surgical markets. Known for its innovative Helium Plasma Technology, Apyx is solely focused on bringing transformative solutions to the physicians and patients it serves. The company’s Helium Plasma Technology is marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. Renuvion offers surgeons and physicians a unique ability to provide controlled heat to the tissue to achieve their desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminating unintended tissue trauma. The Company also leverages its deep expertise and decades of experience in unique waveforms through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com.
Cautionary Statement on Forward-Looking Statements
Certain matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.
Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this release can be found in the Company’s filings with the Securities and Exchange Commission including the Company’s Report on Form 10-K for the year ended December 31, 2019. For forward-looking statements in this release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Westwicke Partners on behalf of Apyx Medical Corporation
Mike Piccinino, CFA